Corcept Therapeutics Incorporated
CORTNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $10.16B
- P/E (TTM)
- 188.14
- Forward P/E
- 459.70
- Dividend yield
- -
- 52-week range
- $28.66$126.38
- Volume (live)
- -
- Avg. volume (3M)
- 1.44M
Corcept Therapeutics Incorporated (CORT) Stock Price & Financial Analysis
Corcept Therapeutics Incorporated Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $84.13 - $106.09 |
|---|---|
| 52-Week High | $126.38 |
| 52-Week Low | $28.66 |
| Open | $106.05 |
| Volume (last close) | 3.10M |
| Average Volume (3M) | 1.44M |
| Revenue (TTM) | 830.81M |
|---|---|
| Net Income (TTM) | 54.03M |
| Free Cash Flow (TTM) | 106.92M |
| EPS (TTM) | $0.47 |
| Profit Margin | 6.50% |
| Operating Margin | 0.77% |
| Return on Equity (ROE) | 7.65% |
| Debt to Equity | 0.01 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 10.16B |
|---|---|
| Shares Outstanding | 118.39M |
| P/E Ratio (TTM) | 188.14 |
| Forward P/E | 459.70 |
| Price to Sales (P/S) | 12.23 |
| Price to Book (P/B) | 14.40 |
| EV/EBITDA | 1461.71 |
| 50-Day MA | $115.71 |
|---|---|
| 200-Day MA | $72.54 |
| 1-Year Change | +47.30% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Corcept Therapeutics Incorporated at a Glance
As of the Oct 23, 2026 close, Corcept Therapeutics Incorporated (CORT) has a market capitalization of $10.16B. The stock trades at 188.1× trailing earnings, 459.7× forward earnings and 12.2× sales. Over the trailing twelve months it earned $54.03M on revenue of $830.81M (a 6.5% profit margin) and generated $106.92M of free cash flow. Revenue grew 16.0% year over year.
As of its latest reported balance sheet, it holds $111.04M in cash and securities against $9.42M of debt, a net cash position of $101.62M.
Corcept Therapeutics Incorporated does not currently pay a dividend.
The share price is up 47.3% over the past year. At $85.86 (the Oct 23, 2026 close) it sits within its 52-week range of $28.66 to $126.38, above its 200-day moving average of $72.54.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $141.00, 64.2% above the Oct 23, 2026 close.
Frequently Asked Questions About Corcept Therapeutics Incorporated
What is the current stock price for CORT?
As of the Oct 23, 2026 close, CORT stock trades at $85.86. The 52-week range is $28.66–$126.38, with a day range of $84.13–$106.09.
What is the P/E ratio for CORT?
As of the Oct 23, 2026 close, Corcept Therapeutics Incorporated's trailing twelve-month (TTM) P/E ratio is 188.1, meaning investors pay $188.1 for every $1 of annual earnings. The forward P/E is 459.7, reflecting analyst expectations for future earnings. Corcept Therapeutics Incorporated operates in the Healthcare sector.
Does CORT pay dividends?
Corcept Therapeutics Incorporated does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for CORT?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for CORT is Buy. The average 12-month price target is $141.00, a 64.2% upside from the Oct 23, 2026 close of $85.86.
What is the market cap of CORT?
As of the Oct 23, 2026 close, Corcept Therapeutics Incorporated's market capitalization is $10.16B, classifying it as a large-cap company. Corcept Therapeutics Incorporated operates in the Healthcare sector within the Biotechnology industry.